4th Quarter - Report

TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$930,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report (this page) Jan 18, 2017 $930,000 Replaced
4th Quarter - Amendment Jan 31, 2017 $1,170,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Patent reform proposals.

Foreign entity interest: Teva Pharmaceutical Industries Ltd., as the indirect parent of Teva Pharmaceuticals USA, has an interest in the issues listed above.

LobbyistCovered position, as disclosed
SUSIE AHN —
DEBRA BARRETT —
SHANNON DZUBIN —
GRANT ERDEL —
ROBERT FALB —

Contacted: U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Pharmacy PHA

Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.

Foreign entity interest: Teva Pharmaceutical Industries Ltd., as the indirect parent of Teva Pharmaceuticals USA, Inc., has an interest in the issues listed.

LobbyistCovered position, as disclosed
SUSIE AHN —
DEBRA BARRETT —
SHANNON DZUBIN —
GRANT ERDEL —
ROBERT FALB —

Contacted: U.S. Trade Representative (USTR); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1353 (114th), H.R. 9 (114th)

Trade (domestic/foreign) TRD

Trans-Pacific Partnership Trade Agreement; Trans-Atlantic Trade & Investment Partnership Agreement.

Foreign entity interest: Teva Pharmaceutical Industries Ltd., as the indirect parent of Teva Pharmaceuticals USA, Inc., has an interest in the issues listed.

LobbyistCovered position, as disclosed
DEBRA BARRETT —
SHANNON DZUBIN —
GRANT ERDEL —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.